Specifications Other Known Titles: Forkhead box protein O4, Proxofim, FOXO4a, AFX, AFX1, MLLT7 Sequence: H-D-Leu-D-Thr-D-Leu-D-Arg-D-Lys-D-Glu-D-Pro-D-Ala-D-Ser-D-Glu-D-Ile-D-Ala-D-Gln-D-Ser-D-Ile-D-Leu-D-Glu-D-Ala-D-Tyr-D-Ser-D-Gln-D-Asn-D-Gly-D-Trp-D-Ala-D-Asn-D-Arg-D-Arg-D-Ser-D-Gly-D-Gly-D-Lys-D-Arg-D-Pro-D-Pro-D-Pro-D-Arg-D-Arg-D-Arg-D-Gln-D-Arg-D-Arg-D-Lys-D-Lys-D-Arg-D-Gly-OH Molecular Formula: C 228 H 388 N 86 O 64 Molecular Weight: 5358.05 g/mol FOXO4-DRI Research DRI peptides are synthetic variants of their natural counterparts
For any injectable, microneedling and/or topical product: we advise that you conduct a patch test and wait in accordance with manufacturer advice (as per the product's packaging and/or enclosed literature) before proceeding to use it
Zappia : Writing review & editing, Writing original draft, Investigation, Formal analysis, Data curation
Patients receiving telitacicept, particularly at a dosage of 240 mg weekly, experienced a substantial reduction in proteinuria, with a mean decrease of 49% from baseline, which was statistically significant compared to the placebo group (P = 0.013)